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Objective: Leukocyte count has been associated with blood pressure, hypertension, and hypertensive
complications. We hypothesized that polymorphisms in the CXCL5 gene, which encodes the neutrophilic
chemokine ENA-78, are associated with blood pressure in cardiovascular disease (CVD)-free adults and that
these polymorphisms are functional.
Methods and results: A total of 192 community-dwelling participants without CVD or risk equivalents were
enrolled. Two CXCL5 polymorphisms (−156 G>C (rs352046) and 398 G>A (rs425535)) were tested for associations
with blood pressure. Allele-specific mRNA expression in leukocytes was also measured to determine whether
heterozygosity was associated with allelic expression imbalance. In −156 C variant carriers, systolic blood pressure
(SBP) was 7 mmHg higher than in −156 G/G wild-type homozygotes (131 ± 17 vs. 124 ± 14 mmHg; P= 0.008).
Similarly, diastolic blood pressure (DBP) was 4 mmHg higher in −156 C variant carriers (78 ± 11 vs. 74 ± 11 mmHg;
P= 0.013). In multivariate analysis of SBP, age, sex, body mass index, and the −156 G>C polymorphism were
identified as significant variables. Age, sex, and the −156 G> C SNP were further associated with DBP, along with
white blood cells. Allelic expression imbalance and significantly higher circulating ENA-78 concentrations were
noted for variant carriers.
Conclusion: CXCL5 gene polymorphisms are functional and associated with variable blood pressure in CVD-free
individuals. The role of CXCL5 as a hypertension- and CVD-susceptibility gene should be further explored.
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The relationship between inflammation and elevated blood
pressure is increasingly being evaluated [1,2]. It has been
shown that elevated concentrations of prototypical pro-
inflammatory markers such as interleukin-6, C-reactive
protein (CRP), and tumor necrosis factor-alpha are
associated with increased blood pressure, incidence of
hypertension, and the likelihood for hypertensive com-
plications [3-14]. It has been further suggested that
this inflammatory-hypertensive relationship results from
increased number or activity of common cellular* Correspondence: abeitels@medicine.umaryland.edu
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distribution, and reproduction in any mediummediators such as white blood cells (WBC) [15,16]. For
example, studies have demonstrated elevated WBC count
to be associated with increased incident hypertension as
well as increased blood pressure within the normal to pre-
hypertensive range [17-22].
Although the exact mechanistic relationship between
leukocytosis and elevated blood pressure is unknown,
it is plausible that low-grade inflammation may be a
contributing factor. In this regard, WBC count may be a
surrogate marker for increased activation of inflammatory
pathways that cause leukocyte recruitment and activa-
tion. As such, increased activity of leukocytic chemokines
could be related to increased blood pressure.
Epithelial neutrophil activator-78 (ENA-78), a key
leukocytic chemokine that is both a neutrophil attractortral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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an inflammatory component (e.g., obesity, diabetes, sub-
clinical atherosclerosis, acute coronary syndromes) [23-32].
We have previously reported that two single nucleotide
polymorphisms (SNPs), -156 G>C (rs352046) and 398
G>A (rs425535), in the gene encoding ENA-78 (CXCL5)
occur in sites important for transcription and exon spli-
cing [33]. In our previous work, a relationship existed
between these SNPs and both plasma concentrations and
leukocyte production of the ENA-78 chemokine protein
[33]. We then went on to show an association between
the CXCL5 -156 G>C polymorphism and worse out-
comes in patients with acute coronary syndromes [27].
In the present work, to the extent that ENA-78 is
important in neutrophil recruitment and degranulation,
we hypothesized that one or both of these polymorph-
isms (−156 G>C and 398 G>A) could be associated
with differences in blood pressure in individuals without
established cardiovascular disease (CVD). Specifically,
we hypothesized that relatively young individuals without
known CVD who were carriers of CXCL5 variant alleles
would exhibit higher systolic blood pressure (SBP), dia-
stolic blood pressure (DBP), or pulse pressure (PP) than
wild-type homozygotes. Furthermore, to assess whether
there was a functional role for these polymorphisms,
we measured allele-specific mRNA expression of CXCL5
in leukocytes obtained from CVD-free individuals who
were heterozygous for the SNPs at both loci.Materials and methods
Study population
The study population has been previously described
[33]. Briefly, participants were recruited from two sites
in the USA and had to be at least 18 years of age with-
out known CVD or CVD-risk equivalents (e.g., diabetes,
peripheral vascular disease, 10-year Framingham Risk
≥20%) as defined by National Cholesterol Education Pro-
gram criteria [34]. Other exclusions were pregnancy,
malignancy, substance abuse, and routine use of medica-
tions known to affect WBC counts such as systemic
steroids and other anti-inflammatory agents. Individuals
were excluded from analysis if they were taking anti-
hypertensive medications for either cardiovascular or
non-cardiovascular indications (e.g., migraine). For blood
pressure measurement, subjects were seated for at least
5 min in a quiet, temperature-controlled General Clin-
ical Research Center (GCRC) outpatient clinic room,
and two blood pressure measurements were taken at
least 5 min apart. The average of the duplicate blood
pressure measurements was used for this investigation.
Blood samples were obtained from participants enrolled
in University of Florida- and Colorado Multiple Institu-
tional Review Board (IRB)-approved studies. All subjectsprovided written informed consent to specimen and data
use in genetic association and related studies.
Genotype and inflammatory biomarker determination
Genomic DNA was isolated from whole blood or buccal
cells using previously described methods [35]. CXCL5
genotypes were determined by polymerase chain reac-
tion (PCR) and pyrosequencing (Qiagen, Valencia, CA,
USA) as we have previously described [36]. Circulating
high-sensitivity CRP (as a non-specific marker of inflam-
mation) was measured by the Shands Hospital Labo-
ratory at the University of Florida and University
of Colorado GCRC. ENA-78 concentrations were mea-
sured by cytometric fluorescence detection as previously
described (Luminex™100 IS system; Luminex Corp.,
Austin, TX, USA; FluorokineW MAP Multiplex Human
Cytokine Panel A; R&D Systems, Minneapolis, MN,
USA) [37]. Samples were stored at −80°C until CRP and
ENA-78 detection was performed.
Allele-specific mRNA quantification
To determine whether variant carrier status results in
functional changes at the transcriptional level, we quan-
tified allele-specific mRNA transcripts from leukocytes
using pyrosequencing-based methodology [38,39]. Spe-
cifically, the presence or absence of allelic expression
imbalance was determined using leukocytes obtained
from 18 individuals who were heterozygotic for both
the −156 G>C and 398 G>A polymorphisms. The
398 G>A SNP was chosen as the genetic biomarker in
these experiments because it is located in the coding re-
gion of CXCL5, while −156 G>C is a promoter poly-
morphism and as such cannot be quantified at the
mRNA level. Because of the near complete linkage of
the studied SNPs, we chose individuals who were het-
erozygotes at both loci so that 398 G>A genotype might
serve as a functional surrogate for the upstream pro-
moter locus.
Leukocyte mRNA was prepared from approximately
6 × 106 cells from each individual using the RNeasy mini
kit (Qiagen, Valencia, CA, USA). Cells were rinsed, lysed,
and homogenized in buffered solutions and subsequently
passed through the RNeasy mini column (Qiagen,
Valencia, CA, USA). Following a series of washes at
room temperature and 15-min incubation with DNase,
concentrations were determined by spectrophotometry
(NanoDrop Technologies, Wilmington, DE, USA).
cDNA was synthesized using approximately 450 ng of
cellular RNA from each individual using a High-
Capacity cDNA Archive Kit (Applied Biosystems, Foster
City, CA, USA) per protocol. Conditions for reverse
transcription were 25°C for 10 min followed by 37°C for
2 h. cDNA quality was assessed by comparing cDNA
and DNA PCR products generated using intron-
Table 1 Baseline characteristics
Characteristic N=192
Age (mean± SD, years) 39 ± 12






Family heart disease history (number (%)) 29 (15.1)
Smoking (number (%)) 35 (18)
Body mass index (mean± SD, kg/m2) 29.6 ± 7
Blood pressure (mean± SD, mmHg)
Systolic 126± 15
Diastolic 75 ± 11
Pulse pressure (mean± SD, mmHg) 51 ± 10





White blood cell count, (mean± SD, ×109 cells/L) 6.3 ± 2.0
C-reactive protein (median (range), mg/Lb) 1.78 (0.1–16.9)
ENA-78 (median (range), pg/mLb) 362 (32.2–3970)
aTotal, HDL, and triglycerides available in 94% of subjects; LDL available in
92% of subjects. bCRP and ENA-78 available for 88% and 91% of subjects,
respectively.
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specific transcript quantification, subject DNA and
cDNA underwent PCR simultaneously using previously
described conditions [36]. PCR products obtained for
genotype determination (DNA) and transcript quantifica-
tion (mRNA) were assayed in parallel pyrosequencing
reactions to minimize cycle variability. Pyrosequencing
analyses were performed in duplicate on three separate
PCR amplification products, and the results were pooled
for analysis. Peak heights were determined by the pyrose-
quencing allele quantification algorithm. In genomic
DNA, the ratio of 398A:G alleles for DNA in heterozy-
gotes is expected to be approximately 1, whereas signifi-
cant deviations from this ratio in mRNA would suggest
allele expression imbalance associated with the variant
allele.
Statistical analyses
Genotype frequencies were determined by allele count-
ing, and departures from Hardy-Weinberg equilibrium
were assessed by chi-square analyses. Differences in
blood pressure by genotype groups (0, homozygous for
common allele; 1, heterozygous or homozygous for vari-
ant allele) were compared using one-way ANOVA.
Based on the preexisting sample size and prevalence of
variant alleles, we had 80% power with a two-sided α of
0.05 to detect a 6-mmHg difference in SBP, 4-mmHg
difference in DBP, and 4-mmHg difference in PP be-
tween genotype groups. Multiple regression analysis was
performed if blood pressure differences were seen across
genotype groups. Covariates for multiple regression were
chosen through univariate analyses of age, sex, smoking
status (0, non-smoker; 1, current smoker), body mass
index (BMI), CRP concentration, ENA-78 concentration,
and WBC count. Any variable with a P ≤ 0.1 on univari-
ate analysis was entered into the multivariable model.
Because of small numbers of individuals within racial
groups, analyses could not be performed within racial
strata. However, race (0, white; 1, non-white) was
included in all multivariable analyses, and a race-by-
genotype interaction term was considered in the regres-
sion models to avoid spurious associations secondary to
racial differences in allele frequency. Multiple regression
using step-type selection methods was performed to
determine the joint effects of CXCL5 genotypes and clin-
ical variables on SBP, DBP, or PP. All statistical analyses
were performed using SPSS (version 11.5, SPSS Inc.,
Chicago, IL, USA) or SAS (version 9.1, SAS Institute
Inc., Cary, NC, USA). A P value < 0.05 was considered
statistically significant.
Results
Baseline demographic characteristics are shown in
Table 1. Participants were on average 39 ± 12 years oldwith blood pressures of 126/75 ± 15/11 mm Hg. -156
G>C and 398 G>A genotypes were determined for 189
and 188 of the 192 individuals, respectively. The overall
−156 C and 398A minor allele frequencies were both
15%. Variant allele frequencies differed by race whereby
the −156 C allele frequency was 14%, 45%, and 11%,
and 398A allele frequency was 13%, 46%, and 9% in
Caucasians, blacks, and non-black Hispanics, respect-
ively. Genotype distributions satisfied criteria for Hardy-
Weinberg equilibrium (data not shown). The two SNPs
were in a high degree of linkage disequilibrium with r2
for Caucasian, black, and Hispanic individuals of 0.82,
1.0, and 0.51, respectively, in our study population.
Genotype association with blood pressure
In −156 C variant carriers, SBP was 7-mmHg higher
than in −156 G/G wild-type homozygotes (131 ± 17 vs.
124 ± 14 mmHg; P= 0.008). Similarly, DBP was 4-mmHg
higher in −156 C variant carriers (78 ± 11 vs. 74 ± 11
mmHg; P= 0.013). PP did not differ between −156 C
variant carriers and wild-type homozygotes (53 ± 11 vs.
51 ± 10; P= 0.22). Because of the high degree of linkage
disequilibrium between the 398 G>A and −156 G>C
Table 2 Multivariate predictors of systolic blood pressure




Constant 100 4.86 <0.0001
Age 0.313 0.094 0.001
Sex −9.84 2.12 <0.0001
BMI 0.637 0.160 <0.0001
−156 C carrier 4.93 2.30 0.034
R2 = 0.325; P< 0.0001.
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compared by 398 G>A genotypes. For example, SBP
was 130 ± 16 and 125 ± 14 mmHg in 398A variant car-
riers and 398 G/G homozygotes, respectively (P= 0.033);
DBP was 78 ± 11 and 74 ± 11 mmHg, respectively
(P= 0.038); and PP was not different between groups
(53 ± 11 vs. 51 ± 10 mmHg in 398A carriers and 398 G/G
homozygotes, respectively; P= 0.362).
Age (P ≤ 0.001), sex (P ≤ 0.008), and BMI (P ≤ 0.002)
were common univariate predictors of SBP, DBP, and
PP. Furthermore, WBC count (P= 0.10 for SBP;
P= 0.076 for DBP) and both CXCL5 polymorphisms
(range P= 0.008 to 0.038) were additional predictors of
SBP and DBP, while smoking status was associated with
SBP alone (P= 0.038). In terms of circulating CRP and
ENA-78 levels, both biomarkers were significant for SBP
(P= 0.005 for CRP and P= 0.033 for ENA-78) and PP
(P= 0.001 for CRP and P= 0.007 for ENA-78) in univari-
ate analyses. Consistent with our previous report,
CXCL5 genotype was associated with ENA-78 protein
concentrations in the plasma whereby variant carriers
at either SNP locus had higher protein concentrations
than wild-type homozygotes (P= 0.003; Figure 1).
In multivariate analysis of SBP, age, sex, BMI, and the
CXCL5 -156 G>C promoter polymorphism were identi-
fied as significant variables (Table 2). The overall model
that included these variables explained 32.5% of the vari-
ability in SBP (P < 0.001). Consideration of the 398 G>A
polymorphism rather than the −156 G>C promoter
SNP resulted in a model in which only age, sex, and
BMI were significantly associated with SBP (R2 = 0.301;








Figure 1 Plasma ENA-78 by CXCL5 -156 G>C genotype.
P= 0.003; data were similar for the exon 2 SNP, data not shown
(P= 0.001).Age, sex, and the −156 G>C SNP were further asso-
ciated with DBP, along with WBC (Table 3). Consider-
ation of this promoter SNP (model R2 = 0.168; P< 0.0001)
was slightly more informative than consideration of the
398 G>A SNP (P=0.067) in which case age (P< 0.0001),
sex (P=0.001), and WBC (P=0.02) still remained signifi-
cant (model R2 = 0.145; P< 0.0001). In multivariable mod-
els of PP, only sex (P< 0.004) and BMI (P< 0.0001) were
significant (model R2 = 0.247; P<0.0001).
Allelic expression imbalance
Allele-specific mRNA quantification was performed to
determine whether there is a functional basis for the dif-
ferences seen in blood pressure based on CXCL5 geno-
types (see ‘Materials and methods’ section for rationale
of 398 G>A as marker SNP). Importantly, there was
consistently higher expression of CXCL5 mRNA from
the 398A allele compared to the 398 G allele in hetero-
zygous individuals (Figure 2A). For example, individual
heterozygotes displayed anywhere from 2.2-fold to 3.4-
fold higher expression of 398A variant transcripts com-
pared to the 398 G allele, with a mean ratio of 2.9
(Figure 2B; P= 7.4E-15).
Discussion
Accumulating evidence points to a relationship between
inflammation and blood pressure. Data suggest that
WBC counts are associated with incident hyperten-
sion and correlated with blood pressure concentrations.
We hypothesized that WBC count is a surrogate forTable 3 Multivariate predictors of diastolic blood




Constant 63.13 3.42 <0.0001
Age 0.247 0.063 <0.0001
Sex −5.801 1.549 <0.0001
−156 C carrier 3.735 1.630 0.023
WBC 0.768 0.374 0.041
R2 = 0.168; P< 0.0001.
Patient ID



































Figure 2 Allele-specific CXCL5 mRNA expression in leukocytes. (A) Allelic mRNA and DNA ratios were measured in 18 cardiovascular
disease-free individuals heterozygous for the 398 G>A SNP. The A/G ratios in DNA were close to 1 suggesting equal abundance of both alleles,
whereas there was consistently higher expression of mRNA from the 398A allele compared to the 398 G allele. (B) Pooled 398A/G ratios from 18
heterozygous individuals. The sample displayed 2.9-fold higher expression of 398A variant transcripts compared to the 398 G allele (P= 7.4E-15).
Data are presented as mean± SD.
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which encodes the neutrophil attractor ENA-78, may be
an important determinant of blood pressure. We demon-
strated a significant, independent relationship between
CXCL5 polymorphisms and SBP and DBP in the overall
population of CVD-free individuals. Variant carriers of the
−156 G>C promoter SNP had 7-mmHg and 4-mmHg
higher SBP and DBP, respectively, than those with the
wild-type −156 G/G genotype. Because of the epidemio-
logically significant difference in CVD risk conferred byblood pressure differences of this magnitude, and since
variant carriers represent approximately 30% of the popu-
lation studied, CXCL5 polymorphisms should be consid-
ered as a potential novel biomarker of pre-hypertension,
hypertension, and CVD risk requiring future study. How-
ever, it is important to emphasize that genetic associa-
tions are preliminary and will require confirmation in
additional populations.
Of particular interest, WBC count (along with trad-
itional variables such as age, sex, smoking status, and
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in univariate analysis among CVD-free individuals. This
finding supports the report by Orakzai et al. that
demonstrated a relationship between WBC counts and
SBP among nearly 3,500 white individuals without CVD
and with SBP<140 mmHg on entry [20]. It also supports
data from other clinical cohorts showing an associa-
tion between WBC count, major WBC components (e.g.,
neutrophils), and blood pressure [21,22,40,41]. However,
in our analysis WBC count was no longer a significant
predictor of SBP when CXCL5 genotype was included in
multivariable analysis, suggesting genotype may capture
the contribution of inflammation to SBP more effectively
than WBC count. WBC did, however, remain a signifi-
cant predictor of DBP in multivariate analysis, along with
age, sex, and CXCL5 -156 G>C genotype.
To determine whether there is any functional basis for
an observed association between CXCL5 variant alleles
and blood pressure, we performed allele expression im-
balance experiments in a subset of participants. The exo-
nic 398 G>A allele was chosen as the genetic marker
given its location in the coding region of the mRNA.
However, the 398 G/A heterozygous individuals (N= 18)
were also heterozygous for the promoter polymorphism,
which minimizes confounding of an association by dif-
fering genotypes at the upstream locus. It was noted that
variant carriers displayed nearly threefold higher expres-
sion of variant CXCL5 mRNA transcripts from the 398A
allele. This novel finding is consistent with our previous
observation that variant carriers exhibited higher plasma
and leukocyte-produced ENA-78 than wild-type homo-
zygotes and that the promoter and exonic SNPs occur in
transcription factor binding and splicing enhancer sites,
respectively [33]. Given that the −156 G>C and 398
G>A SNPs are in near perfect linkage disequilibrium, it
is unclear which polymorphism is the causal variant and
functionally contributes to the blood pressure pheno-
type. However, the −156 G>C promoter SNP was more
significantly correlated with blood pressure in our study.
Further functional studies of these SNPs are warranted.
In addition to genotype and traditional covariates, we
included plasma CRP and ENA-78 protein concentra-
tions in our analyses. While CRP and ENA-78 were sig-
nificantly associated with SBP (and PP) in univariate
analyses, they fell out of the models when CXCL5 geno-
type was included. This suggests that in our analyses,
genotype is more significantly associated with the blood
pressure phenotype than systemically circulating con-
centrations of the non-specific inflammatory mediator
CRP and the CXCL5 protein product ENA-78. While
this observation may appear somewhat contradictory, it
can be postulated that CXCL5 gene polymorphisms may
be better indicators of chemokine activity at the target
organ (e.g., endothelium) level than a measurement in thecirculation. Because of trans-acting influences on
systemic biomarker expression, polymorphisms in CXCL5
may be more robustly associated with blood pressure.
In fact, we have shown a similar finding in a different
population for the endothelial nitric oxide synthase gene
where NOS3 gene polymorphisms, but not measures of
circulating NO activity, were associated with arterial
stiffness in children with type 1 diabetes [42,43]. Further
support for this observation can be found in a case–
control study of the role of ENA-78 in patients with
ischemic stroke. Zaremba et al. demonstrated that
serum ENA-78 protein concentrations were not differ-
ent between stroke patients and controls; contrarily, it
was demonstrated that ENA-78 concentrations were sig-
nificantly higher (twofold) in the cerebrospinal fluid of
stroke patients compared with controls [44]. Taken in
sum, it is possible that genotype more effectively cap-
tures the likelihood for local preponderance of chemo-
kine activity than plasma protein level.
In general, there is biological plausibility for the role of
CXCL5 in CVD. For example, the protein product of
CXCL5, ENA-78, belongs to the same class of chemo-
kines as IL-8, IP-10, and I-TAC, which have been previ-
ously implicated in atherosclerotic inflammation [23,45].
ENA-78 has been shown to be chemotactic for neu-
trophils and stimulate neutrophilic degranulation caus-
ing release of myeloperoxidase and generating reactive
oxygen species [24,25]. In addition, ENA-78 is involved
in platelet-dependent activation of monocytes, displays
angiogenic properties, and has been implicated in diseases
such as obesity, diabetes, subclinical atherosclerosis, acute
coronary syndromes, ischemic stroke, abdominal aortic
aneurysm, and thrombosis [27,28,32,44,46-51]. Hyperten-
sion is a risk factor for adverse events such as atheroscler-
osis, stroke, and abdominal aortic aneurysm, and ENA-78
is overexpressed in these situations. We have shown
CXCL5 polymorphisms to be associated with ENA-78
concentrations, blood pressure, and prognosis following
acute coronary syndromes [27,33]. Thus, the role of
CXCL5 in CVD should be further explored. As final
hypothesis-generating evidence of a link between the
CXCL5 pathway and blood pressure, statins have been
hypothesized to have mild antihypertensive effects, and
we have shown that atorvastatin reduces ENA-78 produc-
tion from human endothelial cells in a dose-dependent
fashion [52,53]. Our findings, along with existing data,
support the need for future investigation of CXCL5 as a
hypertension- and CVD-susceptibility gene.
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